300122 智飞生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-2.482-63.0636.42929.07035.991
总资产报酬率 ROA (%)-1.277-35.4704.00318.36822.157
投入资产回报率 ROIC (%)-1.409-40.6565.14826.58633.585

边际利润分析
销售毛利率 (%)29.1587.84427.36726.97933.631
营业利润率 (%)-20.556-194.9008.63717.78222.889
息税前利润/营业总收入 (%)-16.697-191.8969.01817.81322.820
净利润/营业总收入 (%)-18.310-164.5967.70015.30819.703

收益指标分析
经营活动净收益/利润总额(%)15.37819.436127.992105.136105.691
价值变动净收益/利润总额(%)0.5200.0810.0000.0000.000
营业外收支净额/利润总额(%)0.6540.187-0.452-0.332-0.463

偿债能力分析
流动比率 (X)3.1411.5332.2402.3522.374
速动比率 (X)2.4571.1301.0351.8551.768
资产负债率 (%)45.99149.22438.22037.26336.227
带息债务/全部投入资本 (%)41.36042.88528.0208.0626.763
股东权益/带息债务 (%)139.137130.696254.4901,129.3091,360.295
股东权益/负债合计 (%)115.485101.449161.644168.363176.039
利息保障倍数 (X)-4.180-56.97021.484199.798632.817

营运能力分析
应收账款周转天数 (天)462.295551.884299.953162.179157.502
存货周转天数 (天)253.376594.068296.90779.152109.195